Sanofi reports Q1 business EPS EUR 1.88, up 5% reported

Business EPS was EUR 1.88, up by 14.0% at CER; 5.0% at actual exchange rates; IFRS EPS EUR 1.34. Reports net sales EUR 10/5B, up 6.2% reported and 13.6% at CER. Olivier Charmeil, interim Chief Executive Officer: “We had a strong start to 2026 with double-digit sales and business EPS growth. Sales increased by 13.6%, supported by Pharma launches and recent acquisitions. Dupixent sales were above the EUR 4 billion quarterly mark again and grew by 30.8%. Business EPS was up by 14.0%, reflecting a measured growth of 7.0% in total operating expenses. We obtained five regulatory approvals, all in immunology, achieved one positive phase 3 study readout for venglustat in rare diseases, and reported encouraging phase 2 data for lunsekimig in respiratory diseases. We reiterate our guidance for 2026: we continue to expect sales to grow by a high single-digit percentage and business EPS to grow slightly faster than sales, at constant exchange rates, delivering profitable growth. We are looking forward to welcoming Belen Garijo as the new CEO of Sanofi (SNY) from next month.”